TAMs constrain NK cells’ anti-tumour functions by downregulating activating receptors (NKG2D, 2B4) in NK cells or by expressing distinct immunosuppressive ligands such as PD-L1, GAL9, CD155, GAS6, and TGFβ. This evidence concerns the gene PVR and neoplasm.